Literature DB >> 24334972

Metastatic plasmacytoid urothelial carcinoma: a case report and review of the literature.

Daniel L Olsen1, Scott R Anderson.   

Abstract

Plasmacytoid urothelial carcinoma is a rare form of invasive urothelial carcinoma first described in 1991 by Sahin et al. [Acta Cytol 1991;35:277-280]. Since this original publication, over 70 cases of plasmacytoid urothelial carcinoma have been described. A small number of cytologic descriptions have been published, including cases involving cerebrospinal fluid cytology, bladder washings and urine cytology. To our knowledge, we describe the first fine needle aspiration of metastatic plasmacytoid urothelial carcinoma in a 75-year-old man who presented with a pathologic fracture of the L4 vertebral body. One of the diagnostic pitfalls in the cytologic evaluation of this rare malignancy is the positive staining with CD138. While CD138 is a marker for plasma cell differentiation, it is also positive in plasmacytoid urothelial carcinoma. In addition to recognizing the cytomorphologic details, a full immunohistochemical panel is helpful in properly characterizing this entity. A brief discussion of long-term prognosis and treatment benefit is provided.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24334972     DOI: 10.1159/000356420

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  2 in total

1.  Perirectal recurrence and intraperitoneal dissemination of urothelial carcinoma as plasmacytoid variant: clinical-imaging-histological findings.

Authors:  Miguel Angel Arrabal-Polo; María Del Carmen Cano-García; Paolo Fabiano; Verónica Martínez-Pagán; Matías Barayobre; Javier González García
Journal:  Int Urol Nephrol       Date:  2015-06-07       Impact factor: 2.370

2.  microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1.

Authors:  Tomomi Fujii; Keiji Shimada; Yoshihiro Tatsumi; Kinta Hatakeyama; Chiho Obayashi; Kiyohide Fujimoto; Noboru Konishi
Journal:  BMC Cancer       Date:  2015-10-29       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.